These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221 [TBL] [Abstract][Full Text] [Related]
9. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184 [TBL] [Abstract][Full Text] [Related]
10. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605 [TBL] [Abstract][Full Text] [Related]
11. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084 [TBL] [Abstract][Full Text] [Related]
12. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia. Cha Z; Zang Y; Guo H; Rechlic JR; Olasnova LM; Gu H; Tu X; Song H; Qian B Tumour Biol; 2013 Dec; 34(6):3579-85. PubMed ID: 23807677 [TBL] [Abstract][Full Text] [Related]
13. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598 [TBL] [Abstract][Full Text] [Related]
18. Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders. Nakahashi H; Tsukamoto N; Hashimoto Y; Koiso H; Yokohama A; Saitoh T; Uchiumi H; Handa H; Murakami H; Nojima Y; Karasawa M Cancer Sci; 2009 Apr; 100(4):671-7. PubMed ID: 19220298 [TBL] [Abstract][Full Text] [Related]
19. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913 [TBL] [Abstract][Full Text] [Related]
20. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]